A system was devised to establish the optimum treatment for emesis for each individual child receiving cytotoxic treatment. Cytotoxic drugs were ranked on a scale (1-5), with antiemetic regimens correspondingly graded. An age division (-5 years, >5 years) was included.
Chemotherapy induced emesis is a well recognised complication of the treatment of childhood malignancies. With the current trend towards more intensive treatment schedules it has the potential to impinge greatly on the quality of life of these children.
Recent advances in the field of 5-HT3 receptor antagonists have assisted greatly towards improved antiemetic control.A Such drugs will not be indicated in every case, however. Cytotoxic drugs vary considerably in their emetogenic potential, ranging from nonemetogenic compounds (for example, vincristine) to highly emetogenic treatment (for example, cisplatin). The influence of age must also be considered, with younger children observed to be more tolerant of emetogenic cytotoxic drugs than older children and adults. Finally, budget restrictions imposed on the individual institution may not allow the universal prescription of the relatively expensive 5-HT3 receptor antagonists.
Most centres where children are treated for malignancies will have evolved in-house antiemetic protocols. Flexibility in prescribing to adjust to the individual patient's needs may not be standard practice, however. In addition, such changes are often the responsibility of relatively inexperienced staff. We therefore devised a graded system incorporating standardised antiemetic regimens currently used in our hospital, allowing modifications to suit the individual in a logical stepwise fashion. To assess both the serviceability and efficacy of these guidelines, a prospective criteria based audit was performed.
Subjects and methods The system to be analysed took the form of a modified algorithm (fig 1) . Cytotoxic drugs commonly encountered in the treatment of paediatric malignancies were categorised according to emetogenic potential from low (level 1) to high (level 5). Antiemetic regimens were correspondingly ranked from low (level 1: no antiemetic treatment) to high (level 5: combination antiemetic treatment), with the addition of a 'rescue' combination (level 6) for treatment failure occurring at level 5. Antiemetic regimens were stratified further according to age (A, >5 years; B, -5 years). The guidelines were applied by prescribing the antiemetic regimen corresponding to the level of the most emetogenic cytotoxic drug given each day. In the event of failure at that particular level, stronger antiemetic treatment was given by advancing to the next level.
All children less than 18 years of age attending Bristol Children's Hospital for the administration of cytotoxic treatment between 1 February 1993 and 30 June 1993 were eligible for assessment by audit. Monitoring of emetic control was performed with the aid of diary cards distributed to the nursing staff and the patient or a parent. These cards recorded the number of episodes of vomiting and retching (both diary cards) and nausea (patient card only) for each 24 hour period when chemotherapy was administered and for 48 recorded in the same patient. This was an adolescent with anticipatory symptoms receiving treatment for relapsed disease, but refusing appropriate drugs (see also later sections). If the data from this patient are removed from the analysis (on the grounds that it was not possible to adhere strictly to the suggested guidelines), the course success rate and day success rate become 90% and 93% respectively.
Course failures
Of the 16 children recording course failures with the first course of chemotherapy, five children received further similar treatment during the audit. Three of these children achieved control with the second course of treatment while applying guideline recommendations, and a fourth child required two adjustments before achieving control. The remaining child, with anticipatory symptoms and non-compliant as outlined in the previous section, was not treated successfully. Guidelines for effective control of chemotherapy and radiotherapy induced emesis Anticipatory nausea The patient/parent held diary cards included a brief section to document the presence of anticipatory symptoms before each course of chemotherapy. Six ( 10%) children reported anticipatory problems, but these resolved in five patients with the appropriate alteration of antiemetic treatment as set out in the guidelines. The sixth patient (discussed earlier) refused medication.
Delayed vomiting Delayed vomiting was assessed by recording episodes of vomiting/nausea for a further 48 hours after the end of chemotherapy. Lack of control was reported after treatment containing cyclophosphamide (one of 34 courses assessed in total), ifosfamide (one of six courses), methotrexate (two of 27 courses), and actinomycin (two of 10 courses), one course containing two of the listed drugs. Lack of emetic control had previously been reported in all five patients.
ANALYSIS OF UNSUCCESSFUL CONTROL IN CHEMOTHERAPY
Further scrutiny of the diary cards was performed in an effort to identify level allocation failure of specific cytotoxic treatment. The following were identified: level 2, cytosine 300 mg/M2 (3/3 failures); and level 4, total body irradiation (1440 cGy, eight fractions) (6/13 failures).
ASSESSMENT OF PROTOCOL B (-5 YEARS)
In view of the fact that infants were given specific and differing guidelines, this group, containing 24 children, underwent further analysis. In general, the problems encountered were similar to those already described. It was noted, however, that the option to transfer from level 3B to level 3A was commonly taken (17 of 22 occasions) and not restricted to those patients of borderline age only. This was recorded as staff preference of ease of administration (a 12 hourly rather than a two hourly regimen), particularly during prolonged infusions of cytotoxic treatment.
Discussion
The mechanism of the emetic response is complex, with several sites of action identified and differing antiemetic drugs indicated.5 Although there are many reports of the efficacy of various antiemetic regimens in adults, there is surprisingly little about administration specifically in children. In addition, a survey of paediatric antiemetic practice suggests that the choice of drugs is based on experience rather than clinical trials, and varies considerably from centre to centre.6 The widespread use of phenothiazines, in particular, is reported.6 Steroids have been shown to be effective in the control of moderate emesis,7
and may also be used in combination regimens for highly emetogenic drugs.3
Metoclopramide administration in children and young adults is unfortunately associated with a relatively high incidence of extrapyramidal reactions, particularly when used in high doses, which obviates its widespread use.8 9 The addition of 5-HT3 receptor antagonists to the antiemetic repertoire has been encouraging, with much work reported on their use in adults and children.l1 Dosage schedules vary, but studies in adults and preliminary studies in children suggest that twice daily administration of ondansetron is as effective as more frequent doses.'0 In practice, however, it is not usually single drugs but combinations of treatment that provide the best antiemetic control in difficult cases.
The antiemetic schedules applied in these guidelines incorporated in-house regimens used before the introduction of the guidelines. This ensured familiarity of prescription and delivery at this institution, but may not be universally suitable in other centres. The basic format of the guidelines is such, however, that adaptation to incorporate local policies may be easily achieved.
The audit was undertaken for several reasons. Firstly, the efficacy of the guidelines required analysis. Although the audit criteria set were fairly severe, it is gratifying to note that they were fulfilled in two, and borderline in the third, with the overall levels of antiemetic control well within acceptable limits. The identification of level allocation failures has allowed modifications to be made in the final set of guidelines now in use at our institution (fig 2) . Secondly, the serviceability and general acceptance by the medical and nursing staff required assessment. Although there were several errors made in the initial phase of the audit (these episodes therefore being excluded from the analysis as described), they decreased with time and experience. The main area of dispute was level 3B for the infants, proving cumbersome and time consuming for nursing staff to administer. This level has therefore been omitted from the revised guidelines, and this simplification, together with several minor additional alterations, has resulted in the guidelines in current use (fig 2) .
It is highly desirable to maximise antiemetic treatment in every patient. Often such treatment is prescribed in a non-standardised fashion by junior staff with little experience of oncology. Failure early in the course of a treatment schedule may then be followed by anticipatory symptoms, making for more difficult control. Standardised guidelines provide consistency and have been a great asset in many fields of medical practice. With increasing numbers of available antiemetic drugs and more emetogenic cytotoxic regimens, this was a field we saw to benefit from such a set of guidelines. Although we have incorporated antiemetic regimens previously used in our department, the guidelines could easily be adapted to suit each individual institution, provided they are then assessed adequately by audit. We are pleased to be able to report their efficacy in our practice. 
